Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.

Lucjan Wyrwicz,Elena Elimova,Steven I Blum,H. Xiao,Eric Davenport,Jinyi Wang,Shannon Hunter,Mingshun Li,Kaoru Kondo,Markus Moehler

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.

2021

Lucjan Wyrwicz
Elena Elimova
Steven I Blum
H. Xiao
Eric Davenport
Jinyi Wang
Shannon Hunter
Mingshun Li
Kaoru Kondo
Markus Moehler

4066Background: CheckMate 649 (NCT02872116) is a randomized, open label phase 3 study in first line (1L) GC/GEJC/EAC. Prespecified interim results showed statistically significant improvement in ov...

Keywords:

Internal medicine
Medicine
Nivolumab
in patient
Phases of clinical research
Oncology
Chemotherapy
Interim
Cancer
esophageal adenocarcinoma
Checkmate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations